Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Формат: Artigo
Язык:Inglês
Опубликовано: Wiley 2022-04-01
Серии:Thoracic Cancer
Предметы:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Online-ссылка:https://doi.org/10.1111/1759-7714.14357
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы